Table 4.
Summary of checkpoint inhibitor clinical trials for human cancers. Data taken from http://clinicaltrials.gov/.
| Drug | Combination | Sponsor | Tumor types | Sample size | Phases | Recruitment Status | Clinical trial ID |
|---|---|---|---|---|---|---|---|
| Anti-PD1 antibody | |||||||
| Nivolumab | Tetrahydrouridine | Yogen Saunthararajah | Non Small Cell Lung Cancer | 60 | II | Recruiting | NCT02664181 |
| - | National Cancer Institute (NCI) | Ependymoma, Meningioma, Chordoma | 180 | II | Recruiting | NCT03173950 | |
| TIL infusion | Inge Marie Svane | Metastatic Ovarian Cancer | 12 | I/II | Recruiting | NCT03287674 | |
| - | Hospital Moinhos de Vento | Prostate Cancer | 29 | II | Recruiting | NCT03040791 | |
| Denosumab | Australia and New Zealand Melanoma Trials Group | Metastatic Melanoma | 72 | I/II | Recruiting | NCT03161756 | |
| TAE | Teclison Ltd. | Liver Cancer | 40 | II | Recruiting | NCT03259867 | |
| Viagenpumatucel-L | Heat Biologics | Non Small Cell Lung Cancer | 120 | I/II | Recruiting | NCT02439450 | |
| Radiation | Giuseppe Giaccone | Small Cell Lung Cancer | 56 | I/II | Recruiting | NCT03325816 | |
| Ipilimumab | Bristol-Myers Squibb | Recurrent or Metastatic HNSCC | III | Recruiting | NCT02741570 | ||
| Interleukin-2 | University of Michigan Cancer Center | Metastatic Clear Cell Renal Cell Cancer | 23 | I/II | Recruiting | NCT02989714 | |
| Omaveloxolone or Ipilimumab | Reata Pharmaceuticals, Inc. | Melanoma | 102 | I/II | Recruiting | NCT02259231 | |
| Pembrolizumab | Gemcitabine or Cisplatin | Cedars-Sinai Medical Center | Recurrent Platinum-resistant Ovarian Cancer | 25 | II | Recruiting | NCT02608684 |
| Idelalisib | Zhonglin Hao | Non Small Cell Lung Cancer | 40 | I | Recruiting | NCT03257722 | |
| Docetaxel | Medical University of Vienna | Recurrent or Metastatic Head and Neck Cancer | 22 | I/II | Recruiting | NCT02718820 | |
| INCB001158 | Incyte Corporation | Advanced/Metastatic Solid Tumors | 346 | I/II | Recruiting | NCT02903914 | |
| Vitamin D | Translational Genomics Research Institute | Pancreatic Cancer | 24 | II | Recruiting | NCT03331562 | |
| B-701 | BioClin Therapeutics, Inc. | Advanced or Metastatic Urothelial Cell Carcinoma | 74 | I/II | Recruiting | NCT03123055 | |
| Methotrexate/Docetaxel/Cetuximab | Merck Sharp & Dohme Corp. | Recurrent or Metastatic Head and Neck Cancer | 495 | III | Active, not recruiting | NCT02252042 | |
| Cisplati/Carboplatin/5-FU/Cetuximab | Merck Sharp & Dohme Corp. | Recurrent or Metastatic HNSCC | 825 | III | Active, not recruiting | NCT02358031 | |
| - | Kindai University | Hepatocellular Carcinoma | 50 | II | Not yet recruiting | NCT03337841 | |
| - | Biothera | Advanced MelanomaTriple-Negative Breast Cancer | 95 | II | Recruiting | NCT02981303 | |
| Olaptesed | NOXXON Pharma AG | Colorectal and Pancreatic Cancer | 20 | I/II | Recruiting | NCT03168139 | |
| Laser Interstitial Thermotherapy | Comprehensive Cancer Center | Recurrent Glioblastoma | 34 | I/II | Recruiting | NCT03277638 | |
| Pembrolizumab or Nivolumab | HyperAcute®-Melanoma | NewLink Genetics Corporation | Metastatic Melanoma | 100 | II | Unknown | NCT02054520 |
| IBI308 | Docetaxel | Innovent Biologics (Suzhou) Co., Ltd. | Squamous Cell Lung Carcinoma | 266 | III | Recruiting | NCT03150875 |
| JS001 | - | Shanghai Junshi Bioscience Co., Ltd. | Advanced or Metastatic Bladder Urothelial Carcinoma | 370 | II | Recruiting | NCT03113266 |
| JS001 | - | Shanghai Junshi Bioscience Co., Ltd. | Mucosal Melanoma | 220 | II | Recruiting | NCT03178123 |
| PD-1 Antibodies | - | University Hospital Heidelberg | Melanoma | 40 | II | Recruiting | NCT03171064 |
| Anti-PD-L1 antibody | |||||||
| Atezolizumab | Radiotherapy | Gustave Roussy, Cancer Campus, Grand Paris | Metastatic Tumors | 180 | II | Recruiting | NCT02992912 |
| Guadecitabine | University of Southern California | Acute Myeloid Leukemia | 72 | I/II | Recruiting | NCT02935361 | |
| Atezolizumab | Immune Design | Sarcoma | 88 | II | Active, not recruiting | NCT02609984 | |
| Avelumab | CMB305 | Clinique Neuro-Outaouais | Glioblastoma Multiforme of Brain | 30 | II | Recruiting | NCT03047473 |
| Blocking interaction of PD1 and PDL1 | |||||||
| Durvalumab | Tremelimumab | Samsung Medical Center | Inoperable Esophageal Cancer | 40 | II | Recruiting | NCT03377400 |
| PDR001 | - | Novartis Pharmaceuticals | Advanced Malignancies | 318 | I/II | Recruiting | NCT02404441 |
| Anti-CTLA-4 antibody | |||||||
| Ipilimumab | Nivolumab | Olivia Newton-John Cancer Research Institute | Gastrointestinal Cancer and Neuroendocrine Tumors | 60 | II | Recruiting | NCT02923934 |
| Olaparib | Cediranib | National Cancer Institute (NCI) | Advanced Solid Tumors | 421 | I/II | Recruiting | NCT02484404 |
| CDK4/6 inhibitor | |||||||
| Trilaciclib | Atezolizumab | G1 Therapeutics, Inc. | Small Cell Lung Cancer | 105 | II | Active, not recruiting | NCT03041311 |
| Others | |||||||
| Enfortumab vedotin | Astellas Pharma Global Development, Inc. | Advanced or Metastatic Urothelial Bladder Cancer | 120 | II | Recruiting | NCT03219333 | |
| PV-10 | Dacarbazine | Provectus Biopharmaceuticals, Inc. | Advanced Cutaneous Melanoma | 225 | III | Recruiting | NCT02288897 |
| Anti-OX40 Antibody PF-04 518 600 | Axitinib | University of Southern California | Metastatic Kidney Cancer | 104 | II | Recruiting | NCT03092856 |